Skip to content. | Skip to navigation

European Coalition on Homeopathic & Anthroposophic Medicinal Products

Navigation

RSS feed

ECHAMP response

to Public Consultation Paper Review of the Variations Regulation - Review of Commission Regulation (EC) No 1234/2008

ECHAMP response

to stakeholder consultation on Smart Regulation in the EU - Follow up to the 2012 Communication on Smart Regulation

ECHAMP response

to public consultation on "Which are the TOP10 most burdensome EU legislative acts for SMEs"

October 2015

Follow up to meeting with European Health Commissioner

Braille

Requirements for Braille in the Member States

Common Position (EC) No 61/2003

The Council once more rejected the proposal of a compulsory version of ‘Territory specific rules’ for pre-clinical tests and clinical trials for homeopathic medicinal products not eligible for a special simplified registration in second reading. An extension of the routes of administration under the special simplified registration procedure was also rejected. The proposed amendment introducing a mutual recognition procedure for registered homeopathic medicinal products was only accepted after a compromise proposal (the Council took a negative stance towards a MR for HMP’s during earlier stages of the codecision, but found both Parliament and Commission on its way).

The guidance environment: updates from HMPWG

Newly published documents give a welcome update on the work of the Homeopathic Medicinal Products Working Group of the Heads of Medicines Agencies (HMPWG), including the minutes of its most recent meeting, and important feedback on its work on the justification of homeopathic use and on first safe dilutions.

New ECHAMP position: Suppliers of raw materials

ECHAMP’s new position paper explains why fixing the supplier of raw materials in registration dossiers for homeopathic medicinal products does not in general add to the quality of the product.

ECHAMP response

to public Consultation on Patient Safety and Quality of Care

ECHAMP response

on conference on '50 Years of EU Pharma legislation: Achievements and future perspectives'

ECHAMP response

to the 'External Study Report on the Availability of Medicinal Products for Human Use,’ by Matrix Insight

ECHAMP response

to the communication from the Commission on effective, accessible and resilient health systems

ECHAMP response

to Staff Working Document 'Investing in Health' Accompanying the Document Towards Social Investment for Growth

ECHAMP response

to the consultation on the concept paper on the Introduction of Fees for Pharmacovigilance to be charged by the EMA

ECHAMP response

to the public consultation on the review of Regulation (EC) 1234/2008 article 4: variations guidelines

ECHAMP response

Proposal for a Regulation of the European Parliament and the Council on establishing a Health for Growth Programme, the third multi-annual programme of EU action in the field of health for the period 2014-2020

ECHAMP response

to the European Commission public consultation on the Concept paper " Implementing measures in order to harmonise the performance of pharmacovigilance activities provided for in Directive 2011/83/EC and Regulation (EC) No 726/2004"

ECHAMP response

to EU reflection on chronic disease carried out by the EU Member States and the European Commission

ECHAMP response

to European Commission public consultation on the concept paper "Delegated Act on the detailed rules for a unique identifier for medicinal products for human use, and its verification"

Report on EMEA Workshop on Homeopathic Medicinal Products

Part of the conclusion states: “The level of participation was high and it was greatly appreciated that representatives from users, patients, healthcare professionals, industry and regulators were willing to attend the workshop and have a frank exchange of views concerning current challenges and potential solutions. This report will be transmitted to the European Commission for consideration of the next steps in the area of homeopathic medicinal products.”